TC BioPharm Achieves Major Milestone in Cancer Treatment Releasing Complete Response Data TC BioPharm has reported a complete molecular response in a patient with Minimal Residual Disease after innovative gamma delta T cell therapy, marking a significant milestone.

TC BioPharm Achieves Major Milestone in Cancer Treatment Releasing Complete Response Data #United_Kingdom #Edinburgh #TC_BioPharm #TCB008 #Gamma_Delta_T_Cells

TC BioPharm Completes Cohort A in ACHIEVE Clinical Trial for TCB008 Treatment TC BioPharm announces successful completion of Cohort A in the ACHIEVE clinical trial, showcasing promising results for TCB008 in treating AML.

TC BioPharm Completes Cohort A in ACHIEVE Clinical Trial for TCB008 Treatment #United_Kingdom #Edinburgh #TC_BioPharm #ACHIEVE_Trial #TCB008

TC BioPharm Achieves Milestone with First Patient Dosing in ACHIEVE Trial TC BioPharm celebrates a key achievement in its ACHIEVE trial by administering the initial doses to a patient in Cohort B, paving the way for innovative cancer therapies.

TC BioPharm Achieves Milestone with First Patient Dosing in ACHIEVE Trial #United_Kingdom #Edinburgh #TC_BioPharm #ACHIEVE_Trial #TCB008

TC BioPharm Plans Groundbreaking Studies on H5N1 Treatment Approaches TC BioPharm announces intentions to initiate preclinical studies for TCB008, targeting H5N1, aimed at finding innovative treatments for the viral infection.

TC BioPharm Plans Groundbreaking Studies on H5N1 Treatment Approaches #United_Kingdom #Edinburgh #TC_BioPharm #TCB008 #H5N1

TC BioPharm's ACHIEVE Phase 2b Trial Completes Final Dosing for Patients TC BioPharm announces completion of full-dose regimen in its ACHIEVE Phase 2b trial, with a strong safety profile and promising recruitment figures for 2025.

TC BioPharm's ACHIEVE Phase 2b Trial Completes Final Dosing for Patients #United_Kingdom #Clinical_Trial #Edinburgh #TC_BioPharm #TCB008

TC BioPharm Reports Progress on ACHIEVE Clinical Trial with Promising Safety Data for Cancer Treatment TC BioPharm provides a quarterly update on the ongoing ACHIEVE clinical trial, revealing positive safety data and plans for dose escalation of TCB008.

TC BioPharm Reports Progress on ACHIEVE Clinical Trial with Promising Safety Data for Cancer Treatment #United_Kingdom #Edinburgh #TC_BioPharm #ACHIEVE_Trial #TCB008